AVITA Medical Q2 commercial revenue up 42% to $11.7M; raises FY2023 guidance to $51-53M; two FDA approvals

AVITA Medical, Inc.

2023-Q2 EPS reported $0.78 revenue$22,303,000

Commercial revenue $11.7M (+42% YoY); net loss $0.41/share vs $0.25 loss in prior year.
FDA approved RECELL for full-thickness skin defects (June 7) and vitiligo repigmentation (June 16).
FY2023 revenue guidance raised to $51-53M from prior $49-51M; Q3 guidance $13-14M.
RECELL GO PMA supplement submitted; FDA decision expected by December 27, 2023.
Cash $68.8M, no debt; gross margin guided 83-85% for FY2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

AVITA Medical, Inc. reported second quarter June 30, 2023 results: revenue $11.7 million, net income $10.4 million, EPS $0.41 per share. Guidance raised.

Period: second quarter June 30, 2023
Revenue: $11.7 million
Net income: $10.4 million
EPS: $0.41 per share
Guidance: raised
Result: reported results

Exact text from the filing

Commercial revenue of $11.7 million, a 42% increase compared to $8.2 million for the same period in 2022

View on SEC.gov

12 earnings releases filed in the last 30 days. Browse all earnings releases →

AVITA Medical, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-041292

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.